GleamWall
中文EN

RVMD Revolution Medicines, Inc.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1628171 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-94.6%
TTM EPS YoY-75.9%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-93.6%
ROA-57.1%
ROIC (approx.)-84.1%
Asset turnover—

Leverage & solvency

Liabilities / assets44.2%
Debt / equity0.00x
Current ratio8.36x
Interest coverage-20.62x

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-13.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$0$0
R&D expense$987.33M$592.23M
SG&A expense$195.04M$97.30M
Operating income-$1.18B-$689.52M
Interest expense$24.23M$0
Pretax income-$1.13B-$600.85M
Income tax$0-$753,000
Net income-$1.13B-$600.09M
EBITDA-$1.17B-$682.97M
EPS (basic)-5.95-3.58
EPS (diluted)-5.95-3.58
Weighted avg. shares (diluted)190.13M167.74M
Balance sheet
Cash & equivalents$383.75M$543.06M
Short-term investments$1.64B$1.75B
Receivables$0—
Inventory$0—
Current assets$2.08B$2.33B
PP&E, net$33.19M$24.29M
Goodwill$14.61M$14.61M
Intangibles$55.80M$56.67M
Total assets$2.35B$2.56B
Current liabilities$290.42M$163.91M
Total liabilities$723.21M$293.10M
Shareholders' equity$1.63B$2.27B
Shares outstanding197.00M185.90M
Cash flow statement
Operating cash flow-$897.74M-$557.44M
Capital expenditure$15.99M$10.31M
Free cash flow-$913.73M-$567.74M
Investing cash flow$118.06M-$554.39M
Financing cash flow$621.52M$959.41M
Depreciation & amortization$7.78M$6.56M
Stock-based compensation$118.39M$79.20M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.